Civil Litigation,
Antitrust & Trade Reg.
Feb. 7, 2022
Settlement over generic drug deals gets judge's approval
The settlement is “the third-largest absolute dollar recovery for a direct-purchaser class in a generic delay pharmaceutical antitrust action,” according to U.S. District Judge William H. Alsup’s order.
U.S. District Judge William H. Alsup gave final approval for a $453.85 million settlement to resolve claims of anticompetitive actions and overcharging by pharmaceutical companies.
According to Alsup's order Thursday, this settlement is "the third-largest absolute dollar recovery for a direct-purchaser class in a generic delay pharmaceutical antitrust action" and "the highes...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
